同步放化疗联合尼妥珠单抗治疗食管癌

Concurrent Chemoradiotherapy Combined with Nimotuzumab in the Treatment of Esophageal Carcinoma

目的观察同步放化疗联合尼妥珠单抗治疗食管癌的疗效及毒副反应。方法 33例食管癌患者采用同步放化疗,并于放疗第1天起应用尼妥珠单抗,同时观察疗效及毒副反应。结果 23例既往未接受过放、化疗的患者有效率87.0%,1、2 a总生存率分别为67.0%和45.9%;10例复发和(或)转移的患者有效率90.0%,1 a生存率23.3%,中位生存期8.2个月。主要毒副反应有骨髓抑制、放射性食管炎、胃肠道反应、放射性气管炎,毒副反应程度较轻,均可耐受。结论同步放化疗联合尼妥珠单抗治疗食管癌疗效较好,且患者耐受性好,值得临床进一步研究推广。

Objective To investigate the efficacy and toxicities of concurrent chemoradiotherapy combined with nimotuzumab in the treatment of esophageal carcinoma. Methods Thirty-three patients with esophageal carcinoma were treated by concurrent chemoradiotherapy, nimotuzumab was used from the first day of radiotherapy, and the ef- ficacy and toxicities were evaluated. Results Of all the 23 patients who had not received radiotherapy and chemo- therapy, the effective rate was 87.0% , the 1-, 2-year survival rates were 67.0% and 45.9%. The effective rate of 10 patients who were relapse and （or） metastasis after the treatment was 90.0%, the 1-year survival rate was 23.3%, the median survival time was 8.2 months. The main toxicities were bone marrow suppression, radiation esophagitis, gastrointestinal reaction, radiation bronchitis, all the toxicities were mild and can be tolerated. Conclusion Concurrent chemoradiotherapy combined with nimotuzumab in the treatment of esophageal carcinoma achieved high efficacy, and the toxicities can be tolerated.